



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s) : Miller, et al.
Serial No. : 10/684,136
Filing Date : October 9, 2003
Title : SEBORREIC KERATOSIS TREATMENT

Group/Art Unit : 1651
Examiner : Leon B. Lankford, Jr.
Confirmation No. : 1272

Atty. Docket No. : 766632-0034

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. § 1.56 and § 1.97(b), the references listed below and on the attached Form PTO/SB/08A are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Pursuant to 37 C.F.R. § 1.98(d), copies of the non-patent listed references are not submitted with this Information Disclosure Statement (IDS) in view of the fact that copies of the same have been submitted in an appropriately filed IDS submitted in parent application Serial No. 10/434,805, filed February 8, 2002, from which priority has been claimed in the present application.

Submission of these references is not an admission that the references constitute prior art.

Certificate of Mailing Under 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date: December 27, 2005

Signature: [Signature]

Printed Name: Dyanne Chapman

The Director is hereby authorized to charge any additional amount required, or credit any overpayment, to Deposit Account No. 19-4409.

Applicant respectfully requests that these references be made of record in the above-identified application and considered by the Examiner during prosecution of the application.


It is respectfully submitted that the present invention as claimed is patentable over the listed references.

This information disclosure statement is being filed before the mailing of a first Office Action after the mailing of a request for continued examination under § 1.114. Accordingly, no fee is due.

Acknowledgment of receipt is respectfully requested.

Respectfully submitted,

By: 
Lana M. Knedlik, Reg. No. 42,748
STINSON MORRISON HECKER LLP
1201 Walnut, Suite 2900
Kansas City, MO 64106-2150
Telephone: (816) 842-8600
Facsimile: (816) 691-3495
Attorneys for Margaret Ancira

By: 
David G. Rosenbaum, Reg. No. 31,872
ROSENBAUM & ASSOCIATES, P.C.
650 Dundee Rd., Suite 380
Northbrook, IL 60062
Telephone: (847) 770-6000
Facsimile: (847) 770-6006
Attorneys for Mickey Miller

of 1995, no person

(use as many sheets as necessary)

Attorney Docket Number:	766632-0034
-------------------------	-------------

Sheet	1	of	4
-------	---	----	---

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number:	10/684,136		
		Filing Date:	October 9, 2003		
		First Named Inventor:	Mickey Miller		
		Group Art Unit:	1651		
		Examiner Name:	Leon B. Lankford, Jr.		
Sheet	2	of	4	Attorney Docket Number:	766632-0034

OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS AND INFORMATION			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BEITLER et al., "Association between acrochordons and colonic polyps," <i>J. Am. Acad. Dermatol.</i> , 14: 1042-1044, 1986.	
		BILOTTIA and WAYE, "Hydrogen Peroxide Enteritis: the "Snow White" Sign," <i>Gastrointestinal Endoscopy</i> , 35: 428-430, 1989.	
		CARO, MARCUS RAYNER; and SZYMANSKI, FREDERICK J.: Seborrheic and Senile Keratoses. <i>Medical Clinics of North America</i> 35: 419-431; 1951.	
		CASHMORE, ROBERT W.; and PERRY, HAROLD O.: Differentiating Seborrheic Keratosis from Skin Neoplasm. <i>Geriatrics</i> 40: 69-75; 1985.	
		CHRISTENSEN et al., "Fatal Oxygen Embolization after Hydrogen Peroxide Ingestion," <i>Critical Care Medicine</i> , 20(4): 543-544, 1992.	
		CORNELL and STOUGHTON, "Correlation of the vasoconstriction assay and clinical activity in Psoriasis," <i>Arch Dermatol.</i> , 121: 63-67, 1985.	
		DANIS BODEUR, "The Danger of Hydrogen Peroxide as a Colonic Irrigating Solution," <i>Journal of Pediatric Surgery</i> , 2(2): 131-133; 1967.	
		DICKSON et al., "Hydrogen peroxide exposure—325 exposures reported to a regional poison control center," <i>Clinical Toxicology</i> , 32(6): 705-714, 1994.	
		EBERLIN, J.L.: Curetting for Seborrheic Keratoses. <i>Plastic and Reconstructive Surgery</i> 101(2): 546-547; 1998.	
		ELLIS et al., "Increased epidermal growth factor receptors in seborrheic keratoses and acrochordons of patients with the dysplastic nevus syndrome," <i>J. Am. Acad. Dermatol.</i> , 23: 1070-1077, 1990.	
		GIBERSON et al., "Near-fatal hydrogen peroxide ingestion," <i>Annals of Emergency Medicine</i> , 18: 119-120/778-779, 1989.	
		GOETTE et al., "Skin Blanching Induced by Hydrogen Peroxide," <i>Southern Medical Journal</i> , 70(5): 620-622, 1977.	
		GOETTE, "Hydrogen peroxide-induced skin blanching," <i>Arch Dermatol.</i> , 112: 1788-1789, 1976.	
		GRUBER et al., "The effect of commonly used antiseptics on wound healing," <i>Antiseptics and Wound Healing</i> , 55(4): 472-476, 1975.	
		HENRY et al., "Hydrogen Peroxide 3% Exposures," <i>Clinical Toxicology</i> , 34(3): 323-327, 1996.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number:	10/684,136		
		Filing Date:	October 9, 2003		
		First Named Inventor:	Mickey Miller		
		Group Art Unit:	1651		
		Examiner Name:	Leon B. Lankford, Jr.		
Sheet	3	of	4	Attorney Docket Number:	766632-0034

OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS AND INFORMATION			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		HOCUTT, "Skin cryosurgery for the family physician," <i>American Family Physicians</i> , 48: 445-452, 1993.	
		HUMBERSTON et al., "Ingestion of 35% Hydrogen Peroxide," <i>Clinical Toxicology</i> , 28(1): 95-100, 1990.	
		JONES-CABALLERO, M.; PEÑAS, P.F.; BUEZO, G.F.; FRAGA, J.; and ARAGÜÉS, M.: Malignant Melanoma Appearing in a Seborrheic Keratosis. <i>British Journal of Dermatology</i> 133: 1016-1018; 1995.	
		KLEIN-SZANTO and SLAGA, "Effects of Peroxides on Rodent Skin: Epidermal Hyperplasia and Tumor Promotion," <i>The Journal of Investigative Dermatology</i> , 79: 30-34, 1982	
		LEAVITT et al., "Skin tags: a cutaneous marker for colonic polyps," <i>Annals of Internal Med.</i> , 98: 928-930, 1983.	
		MEVORAH, B.; and MISHIMA Y.: Cellular Response of Seborrheic Keratosis Following Croton Oil Irritation and Surgical Trauma with Special Reference to Melanoacanthoma. <i>Dermatologica</i> 131: 452-464; 1965.	
		MOHS, FREDERIC E.: Seborrheic Keratoses: Scarless Removal by Curettage and Oxidized Cellulose. <i>Journal of the American Medical Association</i> 212(11): 1956-1958; 1970.	
		NANNEY et al., "Altered distribution of phospholipase C- γ 1 in Benign hyperproliferative epidermal diseases," <i>Cell Growth & Differentiation</i> , 3: 233-239, 1992.	
		NANNEY et al., "Epidermal growth factor receptors in idiopathic and virally induced skin diseases," <i>Am. J. Pathology</i> , 140(4): 915-	
		O'TOOLE et al., "Hydrogen Peroxide Inhibits Human Keratinocyte Migration," <i>Dermatologic Surgery</i> , 22: 525-529, 1996.	
		OLIVER and MURPHY, "influenzal Pneumonia: the intravenous injection of hydrogen peroxide," <i>The Lancet</i> , 432-433, 1920.	
		PUMPHREY, "Hydrogen peroxide proctitis," <i>American J. of Surgery</i> , 81: 60-62, 1951.	
		RATHBUN, "A Method for Removing the Acrochordon (Skin Tag)," <i>Kansas Medicine</i> , 91(1): 11-12, 1990.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number:	10/684,136
		Filing Date:	October 9, 2003
		First Named Inventor:	Mickey Miller
		Group Art Unit:	1651
		Examiner Name:	Leon B. Lankford, Jr.
Sheet 4 of 4	Attorney Docket Number:	766632-0034	

OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS AND INFORMATION			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SEBBEN, "The hazards of electrosurgery," <i>J. Am. Acad. Dermatol.</i> , 16(4): 869-872, 1987.	
		SEGAL, "Liquid nitrogen therapy," <i>Australian Family Physician</i> , 13: 356-357, 1984.	
		SOWDEN, J.M.; LEWIS-JONES, M.S.; and WILLIAMS, R.B.: The Management of Seborrheic Keratoses by General Practitioners, Surgeons, and Dermatologists. <i>British Journal of Dermatology</i> 139:348-349; 1998.	
		STROHMER et al., "Use of hydrogen peroxide for vaginal contraception," <i>Human Reproduction</i> , 12: 1599, 1997.	
		STROTHER, "ACROCHORDONECTOMY MADE EASY," <i>Clinician Reviews</i> , 8(3): 154-155, 1998.	
		TEGNER and BJORNBERG, "Hydrogen Peroxide Cream for the Prevention of White Pressure Areas in UVA Sunbeds," <i>Acta Dermatologica Venereologica (Stockholm)</i> , 70: 75-76, 1990.	
		TEGNER, "Induction of Skin Blanching by Hydrogen Peroxide," <i>Acta Dermatologica Venerologica (Stockholm)</i> , 74: 474-475, 1994.	
		TUR et al., "Topical hydrogen peroxide treatment of ischemic ulcers in the guinea pig: blood recruitment in multiple skin sites," <i>Journal of the American Academy of Dermatology</i> , 33: 217-221, 1995.	
		WETMORE, STEPHEN J.: Cryosurgery for Common Skin Lesions: Treatment in Family Physicians' Offices. <i>Canadian Family Physician</i> 45: 964-974; 1999.	
		WINKELMANN, R.K.: Superficial Spreading (and Disappearing) Seborrheic Keratosis. <i>Cutis</i> 63: 235-237; 1999.	
		YAKAR, JONA BEN; SAGI, AMIRAM; MAHLER, DAN; and ZIRKIN, HOWARD: Malignant Melanoma Appearing in Seborrheic Keratosis. <i>Journal of Dermatologic Surgery and Oncology</i> 10: 382-383; 1984.	
		Answer and Counter Claim filed December 2, 2003 in Physicians Choice of Arizona, Inc. v. Mickey Miller, CB-2003-020242 (Superior Court of Arizona, Maricopa County)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.